Results 1 to 10 of about 3,564 (173)
The validated French CFAbd-Score reveals a lower burden of gastrointestinal symptoms in patients on Elexacaftor/Tezacaftor/Ivacaftor. [PDF]
J Pediatr Gastroenterol NutrSermet-Gaudelus I +13 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Tezacaftor for the treatment of cystic fibrosis
Expert Review of Respiratory Medicine, 2018Cystic fibrosis (CF) is the most common, life-limiting autosomal recessive disease in Caucasians, and is caused by defects in production of the CFTR ion channel. Until recently, there were no available treatments targeting the disease-causing defects in CFTR but newly developed CFTR modulators are changing the course of disease in CF.
Marc A Sala, Manu Jain
exaly +3 more sources